



## News Release

August 30, 2021

**FOR IMMEDIATE RELEASE**

### **Biocure Technology Inc. Announces Focus on its own CAR T-cell Therapy Targeting Chronic Lymphocytic Leukemia ("CLL") and Solid Tumor Cancers and Intent to Apply for Patents**

VANCOUVER, British Columbia, August 30th, 2021 -- BioCure Technology Inc. (CSE:CURE; OTCQB: BICTF; FSE: 1WH) ("BioCure" or the "Company") is pleased to provide the following corporate update;

BiocurePharm Corp. ("BPK"), a subsidiary of the Company is excited to announce its focus on the development of its own CAR T-cell therapy targeting Chronic lymphocytic leukemia and solid tumor cancers. BPK is using an innovative concept of ROR1 CAR T-cell therapy combined with a double specific antibody model. In conjunction with the development of its own CAR T, the Company plans to apply for patents covering this CAR T-cell cancer therapy technology.

The CLL market is known to be significantly bigger than the Acute lymphocytic leukemia ("ALL") market and CLL is the most frequent Leukemia occurring in Western countries. The CLL market is being driven by increasing incidence primarily due to aging populations along with the use of combination therapies instead of monotherapies or chemoimmunotherapy regimens. The Company will also be able to apply the same platform technology to develop its CAR T-cell therapy for Solid tumors such as Ovarian and Lung cancers, which provide further enormous opportunities for the Company. The CLL CAR T-cell therapy market is currently not dominated by any single player, compared to the CD-19 CAR T-cell therapy market which has become extremely competitive, dominated by big pharma corporations.

The Company, has recently strengthened its board to focus on its own developed technology and is looking forward to obtaining its own patents where there are currently no restrictions, which is in contrast to CD-19 Car T therapy. The previous work that the Company undertook in the CD-19 CAR T field has been invaluable and given the Company enhanced technical expertise and knowhow for the development of its own new CAR T-cell therapy in addition to its existing Biosimilar development technologies.

Dr. Sang Mok Lee commented, "The Company is extremely excited to be focussing its work in the CAR T-cell cancer therapy field targeting CLL and solid tumors, having spent more than three years to arrive at this stage as a result of its previous work in the CD-19 CAR T and biosimilars space. The CAR T-cell cancer therapy space is one of the most innovative cancer treatments currently in the market and is seeing huge global interest. With the Company developing its own CAR T technologies protected by patents, the company looks forward to driving strong returns for all of its shareholders in the rapidly growing market of CAR T-cell cancer therapy."

### **About Biocure**

Biocure is a leading biotech company developing its CAR-T cell therapy for leukemia, lung, breast and pancreatic cancer. Biocure is in the process of pre-clinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, PEG- Filgrastim as well as Ranibizumab. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis (“MS”) Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes.

ON BEHALF OF THE BOARD OF DIRECTORS

/S/ “SANG MOK LEE”

CEO and Director

For further information, please contact:

Biocure Technology Inc. Telephone: 604-609-7146, or [info@biocuretech.com](mailto:info@biocuretech.com)

*Certain statements in this news release, which are not historical in nature, constitute “forward looking statements” within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company’s proposed activities under the Agreement and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management’s current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements. Neither the Canadian Securities Exchange (the “CSE”) nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.*